C Champeaux1, D Houston2, L Dunn2. 1. Department of neurosurgery, institute of neurological sciences, Queen Elizabeth university hospital, Glasgow, United Kingdom; Department of neurosurgery, Sainte-Anne's hospital, bâtiment Raymond-Garcin, 1, rue Cabanis, 75014 Paris, France. Electronic address: Charles.Champeaux@gmail.com. 2. Department of neurosurgery, institute of neurological sciences, Queen Elizabeth university hospital, Glasgow, United Kingdom.
Abstract
BACKGROUND: To analyse the outcome of patients with WHO grade II meningioma and identify factors that may influence recurrence and survival. MATERIAL AND METHODS: Between January 2000 and October 2016, a retrospective search identified 215 WHO grade II meningiomas operated on at our institution. A survival analysis was conducted on clinical and histological criteria. RESULTS: Eighteen patients (8.4%) had a previous history of grade I meningioma. The cohort underwent a total of 302 surgical resections and 29.7% received radiotherapy. Forty-one patients (19.1%) had been re-operated on for a WHO grade II meningioma relapse. Median follow-up was 4.5 years. At the end of the study, 105 patients (53.6%) had no residual tumour on the last scan. Surgical recurrence-free survival at 5 years was 82%, 95% CI [75.9-88.5]. Secondary grade II meningioma (HR=4.27, P=0.001), Simpson resection grade 1 and 2 vs. 3, 4 and 5 (HR=0.25, P=0.001) and, Ki-67 index (HR=0.22, P<0.001) were independently associated with the surgical recurrence-free survival. Forty-four patients died from their tumours (20.5%). Cause-specific survival probability at 5 years was 83.2%, 95% CI [77.6-89.1]. Age at diagnosis (HR=0.31, P<0.001), Simpson resection grade 1 and 2 vs. 3, 4 and 5 (HR=0.32, P<0.001) and, redo surgery for recurrence (HR=2.39, P=0.010) were independently associated with the cause-specific survival. Patients who received radiotherapy did not demonstrate either a reduced risk of recurrence or a longer survival (P=0.280). CONCLUSION: In this large series, atypical meningioma recurrence correlated with progression from grade I to II, incomplete resection and high Ki-67 index; shorter survival with an older age, incomplete resection, and redo surgery for recurrence. We did not observe a significant improvement in any of the clinical outcomes after radiotherapy.
BACKGROUND: To analyse the outcome of patients with WHO grade II meningioma and identify factors that may influence recurrence and survival. MATERIAL AND METHODS: Between January 2000 and October 2016, a retrospective search identified 215 WHO grade II meningiomas operated on at our institution. A survival analysis was conducted on clinical and histological criteria. RESULTS: Eighteen patients (8.4%) had a previous history of grade I meningioma. The cohort underwent a total of 302 surgical resections and 29.7% received radiotherapy. Forty-one patients (19.1%) had been re-operated on for a WHO grade II meningioma relapse. Median follow-up was 4.5 years. At the end of the study, 105 patients (53.6%) had no residual tumour on the last scan. Surgical recurrence-free survival at 5 years was 82%, 95% CI [75.9-88.5]. Secondary grade II meningioma (HR=4.27, P=0.001), Simpson resection grade 1 and 2 vs. 3, 4 and 5 (HR=0.25, P=0.001) and, Ki-67 index (HR=0.22, P<0.001) were independently associated with the surgical recurrence-free survival. Forty-four patients died from their tumours (20.5%). Cause-specific survival probability at 5 years was 83.2%, 95% CI [77.6-89.1]. Age at diagnosis (HR=0.31, P<0.001), Simpson resection grade 1 and 2 vs. 3, 4 and 5 (HR=0.32, P<0.001) and, redo surgery for recurrence (HR=2.39, P=0.010) were independently associated with the cause-specific survival. Patients who received radiotherapy did not demonstrate either a reduced risk of recurrence or a longer survival (P=0.280). CONCLUSION: In this large series, atypical meningioma recurrence correlated with progression from grade I to II, incomplete resection and high Ki-67 index; shorter survival with an older age, incomplete resection, and redo surgery for recurrence. We did not observe a significant improvement in any of the clinical outcomes after radiotherapy.
Authors: Farshad Nassiri; Justin Z Wang; Karolyn Au; Jill Barnholtz-Sloan; Michael D Jenkinson; Kate Drummond; Yueren Zhou; James M Snyder; Priscilla Brastianos; Thomas Santarius; Suganth Suppiah; Laila Poisson; Francesco Gaillard; Mark Rosenthal; Timothy Kaufmann; Derek S Tsang; Kenneth Aldape; Gelareh Zadeh Journal: Neuro Oncol Date: 2022-05-04 Impact factor: 13.029
Authors: C Leland Rogers; Minhee Won; Michael A Vogelbaum; Arie Perry; Lynn S Ashby; Jignesh M Modi; Anthony M Alleman; James Galvin; Shannon E Fogh; Emad Youssef; Nimisha Deb; Young Kwok; Clifford G Robinson; Hui-Kuo Shu; Barbara J Fisher; Valerie Panet-Raymond; William G McMillan; John F de Groot; Peixin Zhang; Minesh P Mehta Journal: Int J Radiat Oncol Biol Phys Date: 2019-11-29 Impact factor: 7.038
Authors: Taylor Anne Wilson; Lei Huang; Dinesh Ramanathan; Miguel Lopez-Gonzalez; Promod Pillai; Kenneth De Los Reyes; Muhammad Kumal; Warren Boling Journal: Front Oncol Date: 2020-11-20 Impact factor: 6.244
Authors: Sung Kwon Kim; Hong In Yoon; Wan Soo Yoon; Chul Kee Park; Youn Soo Lee; Ho Shin Gwak; Jin Mo Cho; Jangsup Moon; Kyung Hwan Kim; Se Hoon Kim; Young Il Kim; Young Zoon Kim; Ho Sung Kim; Yun Sik Dho; Jae Sung Park; Ji Eun Park; Youngbeom Seo; Kyoung Su Sung; Jin Ho Song; Chan Woo Wee; Se Hoon Lee; Do Hoon Lim; Jung Ho Im; Jong Hee Chang; Myung Hoon Han; Je Beom Hong; Kihwan Hwang Journal: Brain Tumor Res Treat Date: 2020-04